The prediction of cancer recurrence using serum level of CA 19-9 in patients with curative operation of pancreatic cancer in the CONKO 001 cohort

被引：0
|
作者：
Pelzer, U.
Bahra, M. [2 ]
Viol, R. M.
Sinn, M.
Stieler, J. M.
Gebauer, B. [3 ]
Doerken, B.
Oettle, H. [1 ]
Neuhaus, P. [2 ]
Riess, H.
机构：
[1] Charite, Ctr Tumormed, Outpatient Dept Friedrichshafen, D-13353 Berlin, Germany
[2] Charite, Klin Allgemein Visceral & Transplantat Chirurg, D-13353 Berlin, Germany
[3] Charite, Inst Radiol, Abt Neuroradiol & Kinderradiol CCM CVK, D-13353 Berlin, Germany
来源：
ONKOLOGIE | 2012年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：161 / 161
页数：1
相关论文
共 50 条
  • [31] Prognostic significance of serum CA 242 in pancreatic cancer. A comparison with CA 19-9
    Lundin, J
    Roberts, PJ
    Kuusela, P
    Haglund, C
    [J]. ANTICANCER RESEARCH, 1995, 15 (5B) : 2181 - 2186
  • [32] Pretreatment CA 19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine
    Everardo D. Saad
    Marcel C. Machado
    Dalia Wajsbrot
    Roberto Abramoff
    Paulo M. Hoff
    Jacques Tabacof
    Artur Katz
    Sergio D. Simon
    René C. Gansl
    [J]. International Journal of Gastrointestinal Cancer, 2002, 32 : 35 - 41
  • [33] Pretreatment CA 19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine
    Saad, ED
    Machado, MC
    Wajsbrot, D
    Abramoff, R
    Hoff, PM
    Tabacof, J
    Katz, A
    Simon, SD
    Gansl, RC
    [J]. JOURNAL OF GASTROINTESTINAL CANCER, 2002, 32 (01) : 35 - 41
  • [34] SERUM TESTOSTERONE - DIHYDROTESTOSTERONE RATIO AND CA 19-9 IN THE DIAGNOSIS OF PANCREATIC-CANCER
    ROBLESDIAZ, G
    DIAZSANCHEZ, V
    FERNANDEZDELCASTILLO, C
    MORALES, M
    ACEVES, G
    GALVAN, E
    ALTAMIRANO, A
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 1991, 86 (05): : 591 - 594
  • [35] Value of preoperative serum CA 19-9 levels in predicting resectability for pancreatic cancer
    Kilic, Mehmet
    Gocmen, Erdal
    Tez, Mesut
    Ertan, Tamer
    Keskek, Mehmet
    Koc, Mahmut
    [J]. CANADIAN JOURNAL OF SURGERY, 2006, 49 (04) : 241 - 244
  • [36] EVALUATION OF CA 19-9 AS A SERUM TUMOR-MARKER IN PANCREATIC-CANCER
    HAGLUND, C
    ROBERTS, PJ
    KUUSELA, P
    SCHEININ, TM
    MAKELA, O
    JALANKO, H
    [J]. BRITISH JOURNAL OF CANCER, 1986, 53 (02) : 197 - 202
  • [37] CA 19-9 predicts resectability of pancreatic cancer even in jaundiced patients
    Santucci, Nicolas
    Facy, Olivier
    Ortega-Deballon, Pablo
    Lequeu, Jean-Baptiste
    Rat, Paul
    Rat, Patrick
    [J]. PANCREATOLOGY, 2018, 18 (06) : 666 - 670
  • [38] Prognostic value of CA 19-9 in patients with pancreatic cancer treated with Gemcitabine
    Halm, U
    Schuhmann, T
    Keim, V
    Moessner, J
    [J]. GASTROENTEROLOGY, 1999, 116 (04) : A1129 - A1129
  • [39] Serum CA 19-9 Is a Powerful Discriminator of Pancreatic Adenocarcinoma in Patients Referred for ERCP or EUS With Suspected Pancreatic Cancer
    Kwon, Richard S.
    Choksi, Neel
    Scheiman, James M.
    Piraka, Cyrus R.
    Elta, Grace H.
    Elmunzer, B. Joseph
    Young, Benjamin E.
    Prabhu, Anoop
    Wamsteker, Erik-Jan
    Harthun, Kenneth G.
    Brenner, Dean E.
    Anderson, Michelle A.
    [J]. GASTROENTEROLOGY, 2013, 144 (05) : S658 - S658
  • [40] CA 19-9 level predicts response to GTX chemotherapy in pancreatic cancer.
    Fogelman, DR
    Schreibman, SM
    Fine, RL
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 359S - 359S
12345